Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on September 30, 2019. The registrant is a Delaware corporation with principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance data.
Material Changes
The material event reported is the presentation of clinical trial results. On September 28, 2019, the Company presented results from its Phase 1b/2 study of onvansertib in patients with relapsed/refractory acute myeloid leukemia (AML) during an oral plenary session at the 2019 European Society for Medical Oncology (ESMO) Conference in Barcelona, Spain.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the context of the clinical trial presentation. The primary disclosure is the dissemination of the clinical data via a press release furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the clinical data and conclusions presented in the press release (Exhibit 99.1) regarding the onvansertib Phase 1b/2 study.
- Confirm the specific patient population and efficacy metrics reported at the ESMO Conference.
- Review subsequent regulatory filings for any updates on the drug's development timeline or potential partnership discussions triggered by these results.